The Project

• The idea

  An increasing number of personalised therapies block the mutated proteins that drive cancer. However, many of these therapies fail due to cancer’s resistance to drugs. Our new approach aims to make personalised cancer therapies even more personal and thereby longer lasting.

• Inspiration

  By combining classic mutational information (“the hardware of a cancer”) with novel transcriptional information that defines the exact pattern of genes expressed in that particular cancer (“the software of a cancer”), we design and develop combination therapies that will prevent the development of drug resistance.

• Unique selling points

  We believe that our technology has the potential to disrupt the current standard of practice and we envision it as an alternative therapy that offers higher response rates, shortens the treatment window, and provides a cure to patients.

• Societal impact

  Transparent pricing and efficiency reduce trading costs to Despite medical advances, cancer remains a life-altering diagnosis. TOLREMO makes cancer therapies more efficient and longer lasting, resulting in longer life expectancy and better quality of life for patients and reduction in healthcare costs.

• Venture development

  We identified novel drug candidates and are now developing one of our drug prototypes in further preclinical testing. The next step will consist of regulatory safety and toxicity studies, the completion of a data package that supports regulatory approval, and subsequent clinical testing in humans.

• EIT Community support

  The EIT Health Gold Track programme has helped us devise strategies to leverage the full clinical and commercial potential of our solution. EIT Health and Gold Track connected us with C-level experts who also provided personalised support.